ABSTRACT: Orodispersible tablets of carbamazepine were prepared with a view to enhance patient compliance by direct compression method using 3² full factorial design. Crospovidone (2-10% w/w) was used as superdisintegrant and microcrystallinecellulose (0-30% w/w) was used as diluent, along with directly compressible mannitol to enhance mouth feel. The tablets were evaluated for hardness, friability, thickness, drug content uniformity, in vitro dispersion time, wetting time and water absorption ratio. Based on in vitro dispersion time (approximately 10 s); the formulation containing 2% w/w crospovidone and 30%w/w microcrystallinecellulose was found to be promising and tested for in vitro drug release pattern (in pH 6.8 phosphate buffer), short-term stability (at 40º/75 % RH for 3 w) and drug-excipient interaction. This formulation showed four-fold faster drug release (t 25% ) compared to the conventional commercial tablet formulation. Short-term stability studies on the formulation indicated that there are no significant changes in drug content and in vitro dispersion time (p < 0.05).
INTRODUCTION
Dysphagia is a common problem encountered in all age groups in concern to solid dosage forms, which results in high incidence of non-compliance and ineffective therapy. 1 Recent advances in novel drug delivery systems (NDDS) aim to enhance safety and efficacy of drug molecule by formulating a convenient dosage form for administration and to achieve better patient compliance i.e., one, which will rapidly disintegrate in the mouth without need of water (orodispersible tablet). Advantages of this drug delivery system include administration without water, accuracy of dosage, easy portability, alternative to
Correspondence to: P. V. Swamy Tel: +91-8472-221392; Fax: +91-8472-244662 E-mail: vspadavala@rediffmail.com Dhaka Univ. J. Pharm. Sci. 7(1): 1-5, 2008 (June) liquid dosage forms, ideal for pediatric and geriatric patients and rapid onset of action. [2] [3] [4] Carbamazepineb (CBZ) is a dibenzazepine derivative with an anticonvulsant and psychotropic properties. It is used in the treatment of epilepsy, multiple sclerosis, manic depressive illness and painful diabetic neuropathy and trigeminal neuralgia. 5 It was selected as drug candidate, as it is not available in such dosage form. Aim of the present study was to develop such a NDDS for CBZ by simple and cost-effective direct compression method.
MATERIALS AND METHODS
CBZ and crospovidone were gift samples from Nicholas Piramal, Mumbai and Wockhardt Research Centre, Aurangabad respectively. Directly compressi-ble mannitol (Pearlitol SD200), sodium stearyl fumarate and microcrystallinecellulose (Avicel PH-102) were generous gifts from Strides Arco Labs, Bangalore, Glenmark Ltd., Nashik and Alkem Labs Pvt Ltd, Mumbai. All other chemicals were of analytical reagent grade.
Preparation of orodispersible tablets of CBZ.
Orodispersible tablets (OT) of CBZ were prepared by direct compression method 6 according to the formulae given in Table 1 . All the ingredients were passed through #60 mesh separately, weighed and mixed in geometrical order in a tumbling cylindrical blender for 10 min at 15 rpm (fabricated in our laboratory, Fig. 1 ) Then lubricant and glidant (# 200 mesh) were added and mixed for further 5 min. The blend thus obtained was directly compressed using 9.5 mm flat round punches in to tablets of 400 mg on a 10-station rotary tablet machine (Clit, Ahmedabad,India). A batch of 60 tablets was prepared for all the designed formulations. Formulation F 3 was selected as the best and used in further studies F 0 is control formulation, C 1 and C 2 are extra check-point formulations Evaluation of tablets. Twenty tablets were selected at random and weighed individually. The individual weights were compared with the average weight for determination of weight variation. 7 Hardness and friability of the tablets were determined by using Monsanto Hardness Tester and Roche friabilator respectively. For content uniformity test, ten tablets were weighed and powdered, a quantity of powder equivalent to 100 mg of CBZ was extracted into methanol and liquid was filtered. The CBZ content was determined by measuring the absorbance at 285 nm after appropriate dilution with methanol. The drug content was determined using the standard calibration curve. The mean percent drug content was calculated as an average of three determinations.
For determination of wetting time and water absorption ratio, 10 a piece of tissue paper folded twice was placed in a small petri dish(internal duiameter of 5 cm) containing 6 ml of water. A tablet was placed on the paper and the time required for complete wetting was measured. The wetted tablet was then weighed. Water absorption ratio 'R' was determined using the equation, R=100(W b -W a )/W a ; where W a is weight of tablet before water absorption and W b is weight of tablet after water absorption. The results are shown in Table 2 . IR spectra of the pure drug and its formulations were obtained by KBr pellet method using Perkin-Elmer FTIR series (model 1615) spectrophotometer in order to rule out drug-carrier interactions.
Dissolution study. 11 In vitro dissolution of CBZ mouth dissolving tablets was studied in USP XXIII type-II dissolution apparatus (Electrolab, Model-TDT 06N) employing a paddle stirrer at 50 rpm using 900 ml of pH 6.8 phosphate buffer at 37 ± 0.5º C as dissolution medium. One tablet was used in each test. Aliquots of dissolution medium (5 ml) were withdrawn at specified intervals of time and analyzed for drug content by measuring the absorbance at 285 nm. The volume withdrawn at each time interval was replaced with fresh quantity of dissolution medium. Cumulative percent of CBZ released was calculated and plotted against time.
Stability testing. Short-term stability studies on the promising formulation (F 3 ) were carried out by storing the tablets (in amber coloured rubber stoppered vials) at 40º/ 75% RH for 3 w. At intervals of one week, the tablets were visually examined for any physical changes, changes in drug content and in vitro dispersion time.
RESULTS AND DISCUSSION
Mouth dissolving tablets of CBZ were prepared by direct compression method using CP used as superdisintigrant and MCC as diluent along with directly compressible mannitol (Pearlitol SD 200), which serves as a sweetening agent and helps in masking slight bitter taste of the drug. A total of nine formulations and a control formulation (F 0 , without super-disintegrant) were designed.
As the material was free flowing (angle of repose value <30º and Carr's index <15) tablets obtained were of uniform weight (due to uniform die fill), with acceptable variation as per IP specifications (±5%). Drug content was found to be in the range of 95-105%, which is within acceptable limits. Hardness of the tablets was found to be 2.0 to 2.5 kg/cm². Friability below 1% was an indication of good mechanical resistance of the tablets (Table 2 ). Formulation F 3 was found to be promising and displayed an in vitro dispersion time of 15 s, which facilitates faster dispersion in the mouth. In vitro dissolution studies on the promising formulation (F 3 ), the control (F 0 ) and commercial conventional tablet formulation (CF) were carried out in pH 6.8 phosphate buffer and the various dissolution parameter values, viz., percent drug dissolved in 5 min (D 5 ), 10 min (D 10 ), dissolution efficiency 12 at 10 min (DE 10min ), t 25% and t 50% are shown in Table 3 and the dissolution profile depicted in Figure 2 . This data reveals that overall, the formulation F 3 has shown 4-fold faster drug release (t 25% =8.25 min) when compared to CF (t 25% >30 min) and displayed 9-times greater dissolution efficiency at 10 min. The negative sign for coefficients of X 1 and X 2 indicate that as the concentration of disintegrants increases, in vitro dispersion time decreases. The closeness of the predicted and observed values for C 1 and C 2 in the method indicates validity of derived equations for the dependent variable (in vitro dispersion time).
The computer generated response surface and contour plots for the dependent variable are shown in Figures 3 and 4 , respectively.
